{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T04:43:53Z","timestamp":1794717833258,"version":"4.9.1"},"reference-count":49,"publisher":"IntechOpen","isbn-type":[{"value":"9781803560922","type":"print"},{"value":"9781803560939","type":"electronic"}],"license":[{"start":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T00:00:00Z","timestamp":1678838400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/3.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Multiple myeloma accounts for 10% of hematological malignancy and 1% of all cancer. It manifests with anemia, hypercalcemia, renal failure, and bone lesions, with the latter being the most common cause of morbidity. Over the last two decades, many advances were achieved in different aspects of the disease, including, but not limited to risk stratification and treatment approaches. With the approval of Chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma, the main effort in clinical trials is toward studying different CAR T-cell products in different combinations at different disease stages. Although more options are becoming available, more trials are needed to compare their efficacy and safety in the long-term, as well it is essential to consider side effects and quality of life, which will be more noticeable with patients\u2019 lives long after the myeloma diagnosis. There continue to be several unmet needs for multiple myeloma patients, including extramedullary plasmacytoma, plasma cell leukemia, CNS myeloma, and high-risk\/ultra-high-risk disease. These are extremely challenging and further randomized clinical trials are highly needed.<\/jats:p>","DOI":"10.5772\/intechopen.106159","type":"book-chapter","created":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T09:52:57Z","timestamp":1663926777000},"source":"Crossref","is-referenced-by-count":0,"title":["Updates on Multiple Myeloma: What\u2019s New in Risk Stratification, Treatment, and Prognosis"],"prefix":"10.5772","author":[{"given":"Enas","family":"Yahya Mutahar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3774","published-online":{"date-parts":[[2023,3,15]]},"reference":[{"key":"ref=1","doi-asserted-by":"crossref","unstructured":"Landgren O, Weiss BM. Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic\/racial groups: Support for genetic factors in pathogenesis. Leukemia. 2009;23:1691-1697","DOI":"10.1038\/leu.2009.134"},{"key":"ref=2","doi-asserted-by":"crossref","unstructured":"Therneau TM, Kyle RA, Melton LJ III, et al. Incidence of monoclonal gammopathy of undetermined significance and estimation of duration before first clinical recognition. Mayo Clinic Proceedings. 2012;87:1071-1079","DOI":"10.1016\/j.mayocp.2012.06.014"},{"key":"ref=3","doi-asserted-by":"crossref","unstructured":"Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis of monoclonal gammopathy of undetermined significance. The New England Journal of Medicine. 2002;346:564-569","DOI":"10.1056\/NEJMoa01133202"},{"key":"ref=4","doi-asserted-by":"crossref","unstructured":"Kyle RA, Larson DR, Therneau TM, et al. Long-term follow-up of monoclonal gammopathy of undetermined significance. The New England Journal of Medicine. 2018;378:241-249","DOI":"10.1056\/NEJMoa1709974"},{"key":"ref=5","doi-asserted-by":"crossref","unstructured":"Rajkumar SV, Gupta V, Fonseca R, et al. Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma. Leukemia. 2013;27:1738-1744","DOI":"10.1038\/leu.2013.86"},{"key":"ref=6","doi-asserted-by":"crossref","unstructured":"Lakshman A, Paul S, Rajkumar SV, et al. Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance. Leukemia. 2018;32:1811-1815","DOI":"10.1038\/s41375-018-0030-3"},{"key":"ref=7","doi-asserted-by":"crossref","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group Updated criteria for the diagnosis of multiple myeloma. The Lancet Oncology. 2014;15:e538-e548","DOI":"10.1016\/S1470-2045(14)70442-5"},{"key":"ref=8","unstructured":"Palumbo A. Revised international staging system for multiple myeloma: A Report from International Myeloma Working Group. Journal of Clinical Oncology. 2014;33:863-869"},{"key":"ref=9","doi-asserted-by":"crossref","unstructured":"Baysal M. Concepts of double hit and triple hit disease in multiple myeloma, entity and prognostic significance. Scientific Reports. 2020;10:5991","DOI":"10.1038\/s41598-020-62885-0"},{"key":"ref=10","doi-asserted-by":"crossref","unstructured":"Kyle RA, Maldonado JE, Bayrd ED. Plasma cell leukemia. Report on 17 cases. Archives of Internal Medicine. 1974;133(5):813-818","DOI":"10.1001\/archinte.133.5.813"},{"key":"ref=11","doi-asserted-by":"crossref","unstructured":"Carlos Fern\u00e1ndez de Larrea. Primary plasma cell leukemia: Consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage. Blood Cancer Journal. 2021;11(12):192","DOI":"10.1038\/s41408-021-00587-0"},{"key":"ref=12","doi-asserted-by":"crossref","unstructured":"Ramsingh G. A surveillance, epidemiology, and end results database analysis between 1973 and 2004. Cancer. 2009;115(24):5734-5739","DOI":"10.1002\/cncr.24700"},{"key":"ref=13","doi-asserted-by":"crossref","unstructured":"Larsen JT, Chee CE, Lust JA, Greipp PR, Vincent Rajkumar S. Reduction in Reduction in plasma cell proliferation after initial therapy in newly diagnosed multiple myeloma measures treatment response and predicts improved survival. Blood. 2011;118(10):2702-2707","DOI":"10.1182\/blood-2011-03-341933"},{"key":"ref=14","doi-asserted-by":"crossref","unstructured":"Hanne EH. Clinicopathological features of plasmablastic multiple myeloma: A population-based cohort. APMIS. 2015;123(8):652-658","DOI":"10.1111\/apm.12411"},{"key":"ref=15","doi-asserted-by":"crossref","unstructured":"Saad Z. Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents. Haematologica. 2012;97(11):1761-1767","DOI":"10.3324\/haematol.2012.065698"},{"key":"ref=16","doi-asserted-by":"crossref","unstructured":"Avivi I. Hematogenous extramedullary relapse in multiple myeloma \u2013 a multicenter retrospective study in 127 patients. American Journal of Hematology. 2019;94:1132-1140","DOI":"10.1002\/ajh.25579"},{"key":"ref=17","doi-asserted-by":"crossref","unstructured":"Attal M et al. Autologous transplantation for multiple myeloma in the era of new drugs: A phase III study of the Intergroupe Francophone Du Myelome (IFM\/DFCI 2009 Trial). Blood. 2015;126:391","DOI":"10.1182\/blood.V126.23.391.391"},{"key":"ref=18","doi-asserted-by":"crossref","unstructured":"Moreau P, Attal M, Hulin C, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): A randomised, open-label, phase 3 study. Lancet. 2019;394(10192):29-38","DOI":"10.1016\/S0140-6736(19)31240-1"},{"key":"ref=19","doi-asserted-by":"crossref","unstructured":"Voorhees PM, Kaufman JL, Laubach J, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: The GRIFFIN trial. Blood. 2020;136(8):936-945","DOI":"10.1182\/blood.2020005288"},{"key":"ref=20","doi-asserted-by":"crossref","unstructured":"Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Fran\u00e7ais du My\u00e9lome. The New England Journal of Medicine. 1996;335(2):91-97","DOI":"10.1056\/NEJM199607113350204"},{"key":"ref=21","doi-asserted-by":"crossref","unstructured":"Anthony J. Child, High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. The New England Journal of Medicine. 2003;348(19):1875-1883","DOI":"10.1056\/NEJMoa022340"},{"key":"ref=22","doi-asserted-by":"crossref","unstructured":"Kumar SK. Pros and cons of frontline autologous transplant in multiple myeloma: The debate over timing. Blood. 2019;133(7):652-659","DOI":"10.1182\/blood-2018-08-825349"},{"key":"ref=23","doi-asserted-by":"crossref","unstructured":"Srour SA. Melphalan dose intensity for autologous stem cell transplantation (ASCT) in multiple myeloma. American Society for Transplantation and Cellular Therapy. 2019;25(3):S21","DOI":"10.1016\/j.bbmt.2018.12.090"},{"key":"ref=24","doi-asserted-by":"crossref","unstructured":"Scott R. High-Dose Bendamustine, Etoposide, Cytarabine and Melphalan (BeEAM) Conditioning Prior to Autologous Transplantation for Patients with Multiple Myeloma: Results of a Prospective Phase II Trial. Blood. 2021;138(Supplement. 1):1831","DOI":"10.1182\/blood-2021-146091"},{"key":"ref=25","doi-asserted-by":"crossref","unstructured":"Roussel M. Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: An IFM randomized phase 3 study. Blood. 2022;139(18):2747-2757","DOI":"10.1182\/blood.2021014635"},{"key":"ref=26","doi-asserted-by":"crossref","unstructured":"Edward A. Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: Results of the BMT CTN 0702 Trial. Journal of Clinical Oncology. 2019;37:589-597","DOI":"10.1200\/JCO.18.00685"},{"key":"ref=27","doi-asserted-by":"crossref","unstructured":"Attal M. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. The New England Journal of Medicine. 2012;366:1782-1791","DOI":"10.1056\/NEJMoa1114138"},{"key":"ref=28","doi-asserted-by":"crossref","unstructured":"Palumbo A. Autologous transplantation and maintenance therapy in multiple myeloma. The New England Journal of Medicine. 2014;371:895-905","DOI":"10.1056\/NEJMoa1402888"},{"key":"ref=29","doi-asserted-by":"crossref","unstructured":"Philip L. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: A meta-analysis. Journal of Clinical Oncology. 2017;35:3279-3289","DOI":"10.1200\/JCO.2017.72.6679"},{"key":"ref=30","unstructured":"Sonneveld P. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: Results of the Randomized Phase III HOVON-65\/GMMG-HD4 Trial. American Society of Clinical Oncology. 2012;30(24)"},{"key":"ref=31","doi-asserted-by":"crossref","unstructured":"Nooka AK. Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients. Leukemia. 2014;28:690-693","DOI":"10.1038\/leu.2013.335"},{"key":"ref=32","unstructured":"Meletios A, Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): A double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 19 Jan 2019;393(10168):253-264"},{"key":"ref=33","doi-asserted-by":"crossref","unstructured":"Facon T. Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. Blood. 2018;131(3):301-310","DOI":"10.1182\/blood-2017-07-795047"},{"key":"ref=34","doi-asserted-by":"crossref","unstructured":"Brian GM. Longer term follow-up of the randomized phase III trial SWOG S0777: Bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT). Blood Cancer Journal. 2020;10:53","DOI":"10.1038\/s41408-020-0311-8"},{"key":"ref=35","doi-asserted-by":"crossref","unstructured":"Kumar SK. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (E1A11): A multicenter, open label, phase 3, randomized, controlled trial. The Lancet Oncology. 2020;21(10):1317-1330","DOI":"10.1016\/S1470-2045(20)30452-6"},{"key":"ref=36","doi-asserted-by":"crossref","unstructured":"Facon T. Daratumumab plus Lenalidomide,and Dexamethasone for Untreated Myeloma. The New England Journal of Medicine. 2019;380:2104-2115","DOI":"10.1056\/NEJMoa1817249"},{"key":"ref=37","doi-asserted-by":"crossref","unstructured":"Mateos M-V. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): A randomised, open-label, phase 3 trial. The Lancet. 2020;395:10218","DOI":"10.1016\/S0140-6736(19)32956-3"},{"key":"ref=38","doi-asserted-by":"crossref","unstructured":"Giralt S. American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. Biology of Blood and Marrow Transplantation. 2015;21(12):2039-2051","DOI":"10.1016\/j.bbmt.2015.09.016"},{"key":"ref=39","doi-asserted-by":"crossref","unstructured":"Meletios A. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO):an open-label, randomised, phase 3 trial. The Lancet Oncology. 2021;22:801-812","DOI":"10.1016\/S1470-2045(21)00128-5"},{"key":"ref=40","doi-asserted-by":"crossref","unstructured":"Dimopoulos M. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): Results from a randomised, multicentre, open-label, phase 3 study. Lancet. 2020;396:186-197","DOI":"10.1016\/S0140-6736(20)30734-0"},{"key":"ref=41","doi-asserted-by":"crossref","unstructured":"Moreau P. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): A multicentre, open-label, randomised phase 3 trial. Lancet. 2021;397:2361-2371","DOI":"10.1016\/S0140-6736(21)00592-4"},{"key":"ref=42","doi-asserted-by":"crossref","unstructured":"Attal M. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone inpatients with relapsed and refractory multiple myeloma (ICARIA-MM): A randomised, multicentre, open-label, phase 3 study. The Lancet Oncology. 2022 Mar;23(3):416-427","DOI":"10.1016\/S1470-2045(22)00019-5"},{"key":"ref=43","doi-asserted-by":"crossref","unstructured":"Kumar SK. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): A randomised, double-blind, multicentre, phase 3 trial. The Lancet Oncology. 2020;21(12):1630-1642","DOI":"10.1016\/S1470-2045(20)30525-8"},{"key":"ref=44","doi-asserted-by":"crossref","unstructured":"Lonial S. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): A two-arm, randomised, open-label, phase 2 study. The Lancet Oncology. 2020;21:207-221","DOI":"10.1016\/S1470-2045(19)30788-0"},{"key":"ref=45","doi-asserted-by":"crossref","unstructured":"Lonial S. Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-months follow-up from the pivotal DREAMM-2 Study. Cancer. 2021;127(22):4198-4212","DOI":"10.1002\/cncr.33809"},{"key":"ref=46","doi-asserted-by":"crossref","unstructured":"Nikhil C. Idecabtagene Vicleucel in relapsed and refractory multiple myeloma. The New England Journal of Medicine. 2021;384:705-716","DOI":"10.1056\/NEJMoa2024850"},{"key":"ref=47","doi-asserted-by":"crossref","unstructured":"Martin M, Usmani SZ, Berdeja JG, et al. Updated Results from CARTITUDE-1: Phase 1b\/2Study of ciltacabtagene autoleucel, a b-cell maturation antigen\u2013directed chimeric antigen receptor t cell therapy. Patients with Relapsed\/Refractory Multiple Myeloma. Blood. 23 Nov 2021;138(Suppl. 1):549","DOI":"10.1182\/blood-2021-146060"},{"key":"ref=48","doi-asserted-by":"crossref","unstructured":"Amrita Y. Updated Phase 1 Results from MonumenTAL-1: First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed\/Refractory Multiple Myeloma, ASH oral and poster abstract 2021, NCT03399799. Blood. 23 Nov 2021;138(Suppl. 1):158","DOI":"10.1182\/blood-2021-146868"},{"key":"ref=49","doi-asserted-by":"crossref","unstructured":"Moreau P. Updated results from MajesTEC-1: Phase 1\/2 Study of Teclistamab, a B-cell maturation antigen x CD3 bispecific antibody, in relapsed\/refractory multiple myeloma. Blood. 2021;138(Supplement 1):896","DOI":"10.1182\/blood-2021-147915"}],"container-title":["Recent Updates on Multiple Myeloma"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.intechopen.com\/download\/pdf\/83482","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T10:49:20Z","timestamp":1678877360000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.intechopen.com\/chapters\/83482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,15]]},"ISBN":["9781803560922","9781803560939"],"references-count":49,"URL":"https:\/\/doi.org\/10.5772\/intechopen.106159","relation":{"is-part-of":[{"id-type":"doi","id":"https:\/\/doi.org\/10.5772\/intechopen.100849","asserted-by":"object"}]},"subject":[],"published":{"date-parts":[[2023,3,15]]}}}